AXIAL THERAPEUTICS
Live / Registered — Registered (as of 25 Apr 2023)
What this means for you
Registered since 25 Apr 2023. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 88641428
- Registration number
- 7037386
- Mark type
- Stylized text
- Filed
- 03 Oct 2019
- Published for opposition
- 28 Dec 2021
- Registered
- 25 Apr 2023
- Attorney of record
- Ian W. Gillies
Goods and services
- Class 001 — Chemicals: Chemicals, biochemicals, cells, and microbes for use in the manufacture of probiotic or microbe-targeted pharmaceutical preparations, for in vitro and in vivo scientific or research use, and for use in industry and science; chemical, biochemical and microbial products, namely, one or more of small molecules, proteins, antibodies, nucleic acids, probiotic bacteria, probiotic bacterial cultures, and microbes for the manufacture of probiotic or microbe-targeted pharmaceutical preparations for the treatment, prevention, and detection of central nervous system diseases and disorders, cancer, tumors, fibrosis, inflammation, microbe-related and microbiome-related conditions, gastrointestinal and immunological diseases, and any disease or disorder associated with intestinal permeability, or leaky gut, and amyloids
- Class 005 — Pharmaceuticals: Probiotic or microbe-targeted pharmaceutical preparations and substances for the treatment, prevention, and detection of central nervous system diseases and disorders, cancer, tumors, fibrosis, inflammation, microbe-related and microbiome-related conditions, gastrointestinal and immunological diseases, and any disease or disorder associated with intestinal permeability, or leaky gut, and amyloids; chemical, biochemical and microbial products, namely, one or more of small molecules, proteins, antibodies, nucleic acids, probiotic bacteria, probiotic bacterial cultures, and microbes being pharmaceutical preparations and substances for the treatment, prevention, and detection of central nervous system diseases and disorders, cancer, tumors, fibrosis, inflammation, microbe-related and microbiome-related conditions, gastrointestinal and immunological diseases, and any disease or disorder associated with intestinal permeability, or leaky gut, and amyloids
- Class 042 — Scientific and technological services: Providing medical and scientific research information in the fields of pharmaceuticals, biochemistry, biotechnology, and clinical trials; drug discovery services; pharmaceutical research; research and development of new probiotic or microbe-targeted phamaceutical products; research in the fields of biochemistry, biotechnology, and conducting clinical trials for others
- Class 044 — Medical, beauty and agricultural services: Providing medical information in the fields of diagnostic, prophylactic, and therapeutic properties of probiotic or microbe-targeted pharmaceuticals
Owner
- AXIAL THERAPEUTICS, INC., WOBURN, MA, US
- AXIAL THERAPEUTICS, INC., WOBURN, MA, US
- Axial Biotherapeutics, Inc., Waltham, MA, US
Prosecution history
- 25 Apr 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 25 Apr 2023 — REGISTERED-PRINCIPAL REGISTER
- 21 Mar 2023 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 18 Mar 2023 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 22 Feb 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 21 Feb 2023 — STATEMENT OF USE PROCESSING COMPLETE
- 17 Feb 2023 — USE AMENDMENT FILED
- 21 Feb 2023 — SOU EXTENSION 2 GRANTED
- 17 Feb 2023 — SOU EXTENSION 2 FILED
- 17 Feb 2023 — SOU TEAS EXTENSION RECEIVED
- 17 Feb 2023 — TEAS STATEMENT OF USE RECEIVED
- 05 Oct 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 04 Oct 2022 — SOU EXTENSION 1 GRANTED
- 22 Aug 2022 — SOU EXTENSION 1 FILED
- 01 Sept 2022 — CASE ASSIGNED TO INTENT TO USE PARALEGAL